Bionomics, an Australian Phase 2 biotech developing allosteric ion channel modulators for CNS disorders, raised $20 million by offering 1.6 million ADSs at $12.35, below the as-converted last close of its shares on the ASX ($15.66). Insiders had indicated on $15 million worth of ADSs in the offering (75% of the deal).
Bionomics is developing novel, allosteric ion channel modulators for patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. The company is advancing its lead candidate, BNC210, an oral proprietary selective negative allosteric modulators of the α7 receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). It expects to initiate its Phase 2 PREVAIL trial of BNC210 for SAD by the end of 2021, with topline data anticipated by the end of 2022, and has initiated its Phase 2b ATTUNE trial of BNC210 for PTSD, with topline data anticipated in the 1H23.
Bionomics plans to list on the Nasdaq under the symbol BNOX. Evercore ISI, William Blair, and Cantor Fitzgerald acted as joint bookrunners on the deal.
